|
The role of c-Maf in Stem cells in Leukemia
|
5F31CA162770-05
|
|
$0
|
OKOYE, UJUNWA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
The role of c-Maf in Stem cells in Leukemia
|
6F31CA162770-06
|
$43,120
|
$21,560
|
OKOYE, UJUNWA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma
|
5R44CA167925-03
|
$750,000
|
$750,000
|
WONG, HING
|
ALTOR BIOSCIENCE CORPORATION
|
|
Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma
|
1R44CA199767-01
|
$666,666
|
$666,666
|
SMITH, CHARLES
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
Integrated Systems for the Analysis of Circulating Multiple Myeloma Cells (CMMCs)
|
1R44CA203221-01
|
$808,983
|
$808,983
|
HUPERT, MATEUSZ
|
BIOFLUIDICA, INC
|
|
Sensitivity of multiple myeloma cells to mTOR inhibitors
|
5R01CA111448-09
|
$184,270
|
$184,270
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S1
|
$34,176
|
$684
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S2
|
$810,357
|
$16,207
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-02
|
$9,967,453
|
$199,349
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Diet patterns, aspirin use, obesity and multiple myeloma: a prospective analysis
|
1R21CA198239-01
|
$252,155
|
$252,155
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S1
|
$37,026
|
$1,481
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S2
|
$49,999
|
$2,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-25
|
$4,878,887
|
$195,155
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-01S1
|
$171,796
|
$4,295
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-02
|
$1,360,245
|
$34,006
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental Co
|
7R01CA138688-07
|
$327,043
|
$327,043
|
LI, YONG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma
|
5R01CA163881-05
|
$395,129
|
$395,129
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Elucidating the role of microRNAs in the initiation of multiple myeloma
|
4R00CA172292-03
|
$248,999
|
$248,999
|
ZHAO, JIANJUN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Cancer Center Support Grant
|
3P30CA013696-41S1
|
$120,000
|
$1,200
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S2
|
$60,000
|
$600
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S3
|
$125,000
|
$1,250
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S4
|
$157,133
|
$1,571
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-41
|
$3,792,720
|
$37,927
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
1R01CA193890-01
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of MMP13 in Multiple Myeloma Bone Disease
|
5R01CA175313-02
|
$331,098
|
$331,098
|
LENTZSCH, SUZANNE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
SPORE in Multple Myeloma
|
5P50CA100707-13
|
$2,185,000
|
$2,185,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-23
|
$301,545
|
$301,545
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S1
|
$122,500
|
$3,675
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S2
|
$50,000
|
$1,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S3
|
$125,000
|
$3,750
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S4
|
$200,000
|
$6,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S5
|
$62,500
|
$1,875
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
5P30CA006516-50
|
$11,162,542
|
$334,876
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
5U10CA180867-02
|
$1,171,980
|
$29,300
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
Validating the eCyPA/CD147 signaling complex for myeloma therapy
|
1R01CA196783-01
|
$393,715
|
$393,715
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INST
|
|
Dual STAT3/NF-kB Inhibitors for Targeted Cancer Therapy
|
5R01CA160979-04
|
$363,125
|
$181,563
|
FRANK, DAVID
|
DANA-FARBER CANCER INST
|
|
The role of miRNA15a and 16-1 in Multiple Myeloma
|
5R01CA154648-05
|
$363,125
|
$363,125
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
Stroma-mediated clonal evolution in Multiple Myeloma
|
5R01CA181683-02
|
$353,786
|
$353,786
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
Development and Application of Selective Covalent Cdk7 Inhibitors
|
5R01CA179483-02
|
$503,599
|
$503,599
|
GRAY, NATHANAEL
|
DANA-FARBER CANCER INST
|
|
ECOG-ACRIN Network Group Statistics and Data Management Center
|
5U10CA180794-02
|
$6,421,209
|
$128,424
|
GRAY, ROBERT
|
DANA-FARBER CANCER INST
|
|
Functional and biologic significance of deacetylase3 inhibition in myeloma
|
5R01CA178264-02
|
$353,291
|
$353,291
|
HIDESHIMA, TERU
|
DANA-FARBER CANCER INST
|
|
Determining the mutational landscape of circulating multiple myeloma cells
|
1K08CA191026-01A1
|
$177,120
|
$177,120
|
LOHR, JENS
|
DANA-FARBER CANCER INST
|
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-05
|
$1,988,528
|
$1,988,528
|
MUNSHI, NIKHIL
|
DANA-FARBER CANCER INST
|
|
Occupational Pesticide Use and Risk of Lymphoid Cancers
|
1R03CA199515-01
|
$78,250
|
$25,823
|
DE ROOS, ANNECLAIRE
|
DREXEL UNIVERSITY
|
|
Targeting sphingosine kinase 2 for the treatment of multiple myeloma
|
1R01CA197792-01
|
$363,713
|
$363,713
|
KANG, YUBIN
|
DUKE UNIVERSITY
|
|
Cancer Center Support Grant
|
2P30CA014236-41
|
$5,661,203
|
$56,612
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA014236-41S1
|
$56,234
|
$562
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
ECOG-ACRIN Operations Center
|
3U10CA180820-02S1
|
$249,446
|
$4,989
|
COMIS, ROBERT
|
ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
|
|
ECOG-ACRIN Operations Center
|
3U10CA180820-02S2
|
$195,075
|
$3,902
|
COMIS, ROBERT
|
ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
|
|
ECOG-ACRIN Operations Center
|
3U10CA180820-02S3
|
$324,849
|
$6,497
|
COMIS, ROBERT
|
ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
|
Total relevant funding to Multiple Myeloma for this search: $48,874,500
|